GBP2’s beneficial effects in breast cancer contrast with its role in driving malignancy in renal carcinoma, necessitating precise targeting strategies, which can be evaluated through tumor-specific expression profiling or patient stratification [25,36]. This evidence concerns the gene GBP2 and breast cancer.